Filter posts

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City …

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks …

Greenwood Highlights Role of Innovation in Solving Opioid Crisis

The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in …

Senate Has the Power to Expand Access to Medication for Opioid Addiction

BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the …

Greenwood comment on PABNAB

BIO and BIO’s Board-level Workforce Development, Diversity and Inclusion (WDDI) Committee were disappointed that the …

Lupus Patients Find Hope In the Face of Hardship

One and a half million and counting. That’s how many people suffer from lupus in …

On the President’s Drug Cost Plan, Three Important Concerns

Part 1. Restricting access under Medicare Part D  The Trump administration is out with its …

Diversity in Biopharma Leadership Makes Dollars and Sense

A series of recent studies examining diversity and financial performance have fueled a growing insistence …

The Latest Good News on Prescription Drug Costs

Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These …